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Summary
 Background: Tuberculosis (TB) is a major post-transplant concern in endemic areas. This report 
summarizes the clinical characteristics, risk factors, and effects of post-transplant TB 
on graft and patient survival at a single center in Korea.
 Material/Methods: We retrospectively analyzed data from 2799 kidney recipients at Yonsei University 
Health System between April 1979 and August 2008 to determine the incidence, out-
come, and risk factors affecting the development of TB infections and the effect of 
TB on graft and patient survival rates.
 Results: TB developed in 144 (109 males and 35 females; mean age, 37±12 years) out of 2799 
(5.1%) recipients. Newly developed TB occurred in 116 recipients (81%) and recur-
rent TB occurred in 28 (19%) recipients with a pre-transplant history of a mycobac-
terial infection. The mean interval to TB diagnosis was 55.6±47.9 months after trans-
plantation without a peak interval incidence for 8 years after transplantation. Based on 
Cox regression analysis, a history of TB was the strongest risk factor (hazard ratio [HR] 
=11.618) affecting the development of TB. TB negatively affected graft and patient sur-
vival after kidney transplantation. Non-pleurisy extrapulmonary and miliary TB result-
ed in inferior treatment results and a poor prognosis in the early treatment period.
 Conclusions: A history of TB is the strongest predictor of post-transplant TB. Therefore, patients 
with a pre-transplant history of TB should be carefully monitored.
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Background
Tuberculosis (TB) remains an infectious disease 
problem in many countries, especially in endem-
ic areas. Although continuous efforts to prevent 
this disease from spreading are in progress, the 
prevalence of TB has not decreased in recent 
years. According to a 2008 WHO report, there 
were an estimated 9.2 million new cases of TB in 
2006 (139 per 100 000 population) worldwide. 
This increase from 9.1 million cases in 2005 has 
been ascribed to population growth [1]. TB in 
immunocompromised transplant recipients is 
more complicated and has a higher incidence 
than in the general population, and can lead to 
graft loss and patient death. The reported inci-
dence in the transplant population ranges from 
0.8–13.3% [2–10]. Interactions with immuno-
suppressive agents and the toxicity of anti-tuber-
cular drugs make treatment of TB an enormous 
challenge after transplantation. This report sum-
marizes the clinical characteristics, risk factors, 
efficacy, and safety of an anti-tuberculosis pro-
tocol, and the effect on graft and patient surviv-
al of post-transplant tuberculosis infections at a 
single center in an endemic area.
Material and Methods
Patients
We conducted a retrospective study of all renal 
transplantation recipients between April 1979 
and August 2008 at Yonsei University Health 
System. To find recipients with post-transplant 
TB, we retrospectively reviewed the medical re-
cords of the 2799 recipients in the transplant da-
tabase. All of the patients who were diagnosed 
with post-transplant TB were reviewed for demo-
graphic features, immunosuppressive treatment, 
the length of time between transplantation and 
diagnosis of TB, involved organs, treatment pro-
tocols, adverse effects, and the effect on graft and 
patient survival.
Immunosuppressive protocol
Prior to 1984, the immunosuppressive agents 
were azathioprine (AZA) and prednisolone; 
thereafter, a double regimen with cyclosporine 
A (CsA) and prednisolone or a triple regimen 
in which AZA or mycophenolate mofetil (MMF) 
was added was used. Since 1998, tacrolimus has 
been used instead of CsA. Induction immunosup-
pression therapy (anti-thymocyte globulin, anti-
lymphocyte globulin, and muromonab-CD3) was 
not used; however, induction therapy with the in-
terleukin-2 receptor antibody (basiliximab) has 
been used for high-risk recipients from deceased 
or unrelated living donors, except for zero-anti-
gen mismatched donors, since 1999. MMF was 
introduced in 1997 and added for appropriate 
recipients as a triple regimen with a calcineurin 
inhibitor and steroids, which was previously used 
for a double regimen.
Steroid pulse therapy (methylprednisolone [500 
mg/day ×4 for 5 days]) was considered the first-
line therapy for acute rejection. When there was 
an inadequate response to steroid pulse thera-
py, an anti-lymphocyte antibody (ALA), such as 
OKT-3 or the anti-thymocyte antibody, was used. 
Graft loss was defined as patient death, graft re-
moval, or conversion to regular dialysis.
Diagnosis of tuberculosis
TB was diagnosed by 1 or more of the fol-
lowing methods: (1) demonstration of acid-
fast bacilli (AFB) in a bronchoalveolar lavage 
(BAL), sputum, or pleural fluid sample, and/or 
Mycobacterium tuberculosis growth in culture media; 
(2) demonstration of a caseating granuloma and 
positive results on an AFB smear for tissue histol-
ogy; (3) demonstration of TB DNA using a poly-
merase chain reaction (PCR); and (4) a favora-
ble response to anti-tubercular drugs in patients 
with clinical symptoms and typical radiograph-
ic findings consistent with TB, or those who had 
a fever of unknown origin despite negative re-
sults of other extensive investigations. These di-
agnoses included definite, probable, or suspect-
ed cases. A pre-transplant history of tuberculosis 
was defined as a history of undergoing anti-tu-
berculosis treatment before the transplantation, 
with or without confirmation of post-TB inflam-
matory scarring on a pre-transplant chest X-ray. 
According to the WHO classification, we subclas-
sified TB as follows: (1) pulmonary type of TB, 
including pulmonary TB and miliary TB involv-
ing lung lesion; and (2) extrapulmonary type of 
TB, including TB pleurisy and non-pleurisy ex-
trapulmonary TB.
Anti-tuberculosis protocols
The anti-tubercular regimen was comprised of 
multiple combinations of isoniazid (INH), eth-
ambutol (EMB), rifampicin (RFP), streptomy-
cin (SM), and pyrazinamide. In the pulmonary 
type of TB, 6–12 months of treatment was rec-
ommended and >12 months of treatment was 
Original Paper Ann Transplant, 2013: 18: 163-173
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recommended for the extrapulmonary type of 
TB. The calcineurin inhibitor was adjusted by 
the trough level during the use of anti-tuber-
culosis medication because the RFP-based regi-
men decreased the trough level of the calcineu-
rin inhibitor.
Statistical analysis
The cumulative incidence of post-transplant TB 
was calculated by the Kaplan-Meier method. Risk 
factors for post-transplant TB were recipients age 
and sex, pre-transplant history of TB, hepatitis B vi-
rus (HBV) antigenemia (HBsAg-positive), hepatitis 
C virus (HCV) infection (anti-HCV antibody-posi-
tive), diabetes (including post-transplant diabetes), 
an acute rejection episode, and a major immuno-
suppressive agent. To compare the cumulative in-
cidence for each risk factor, univariate analysis was 
performed with the Wilcoxon method. A Cox haz-
ards proportional regression model, taking into ac-
count the interactions between the aforementioned 
factors, was used to identify the risk factors for post-
transplant TB. We divided the transplant era into 3 
periods (before 1984, 1984–1986, and after 1997) 
according to the change in the immunosuppres-
sive regimen and prevalence of TB in the gener-
al population in Korea. Before 1984, AZA was the 
only major immunosuppressive agent; thereafter, 
CsA gradually replaced AZA. Before 1997 the preva-
lence of TB in the general population of Korea was 
about 3 times higher than after 1997 and reached 
a plateau until recently [11].
The results of the Cox regression test are present-
ed as the hazard ratio (HR), the 95% confidence 
interval (CI), and P-values. The graft and pa-
tient survival rates were calculated by the Kaplan-
Meier method and compared with a Wilcoxon 
test. Student’s t-test or chi-square test was used to 
analyze the characteristics of each subgroup. All 
statistical analyses were performed using SPSS® 
14.0 for Windows (SPSS, Inc., Chicago, IL, USA).
results
Demographic data
Among 2799 recipients, 144 recipients were di-
agnosed with post-transplant TB during a mean 
follow-up period of 164±73.2 months (range, 
2–320 months) after transplantation. The over-
all cumulative incidence of TB was 5.1%. The 
109 male and 35 female subjects had an over-
all mean age at diagnosis of 41.5±12.2 years and 
a mean time interval between transplantation 
and TB diagnosis of 55.6±47.9 months (range, 
0–225 months). Of the 144 post-transplant TB 
patients, 28 patients had a pre-transplant history 
of TB that was cured completely and showed no 
activation on the chest X-ray performed as part 
of the pre-transplant evaluation. All 28 patients 
with pre-transplant TB history had received ap-
propriate anti-tuberculosis treatment, had been 
diagnosed as completely cured, and needed no 
more further treatment. However, there were no 
medical records because the treatments of pre-
transplant TB were performed in other institutes 
many years previously in all patients.
The mean interval between transplantation and 
TB diagnosis of the 28 patients who had a pre-
transplant history of TB was 50.4±35.8 months, 
which was not different from the 116 patients 
without a pre-transplant history of TB (56.9±50.5 
months; P=0.524).
The time table of the post-transplant TB presen-
tation is shown in Figure 1, which includes the in-
terval incidence by post-transplant period. There 
were no significant peak interval incidences in 
each year within the 8 years following transplan-
tation. The overall cumulative incidence of TB 
10 and 20 years after transplantation was 6.1% 
and 8.9%, respectively.
The most common symptom of TB in nearly all 
of the patients was pyrexia; however, in 25 cas-
es there were no significant symptoms related to 
TB (17.4%). The most common diagnostic tool 
was clinical symptoms with pathologic findings 
on chest radiographs in 56 patients (38.9%). 
Thirty-nine patients (27.1%) had an AFB stain 
from sputum, tissues, or pleural fluid at presen-
tation. A positive TB PCR existed in 11 patients 
(7.6%), a positive culture in 6 patients (4.2%), 
demonstration of caseating granuloma in histol-
ogy in 24 patients (16.7%), and a positive aden-
osine deaminase (ADA) in 8 patients (5.5%).
Risk factor analysis of post-transplant TB
Based on univariate risk factor analysis, a pre-
transplant history of TB, AZA-based immuno-
suppression, acute rejection history, male sex, 
post-transplant diabetes mellitus (PTDM), HBV 
carrier, and transplant era before 1997 were risk 
factors for post-transplant TB; HCV infection 
was not a risk factor for TB (data not shown). 
Table 1 shows the differences of the clinical fea-
tures between the non-TB and post-transplant 
TB patients.
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Based on multivariate risk factor analysis, it ap-
pears that before 1984 there were no significant 
risk factors for post-transplant TB. In this era, 
there were no HCV carriers and no recipients 
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Figure 1.  Time table of tuberculosis presentation. The mean interval between transplantation and TB diagnosis was 56±47.9 months (range, 
0~225 months).
Variables Post-transplant TB group (n=144)
Non-TB group 
(n=2,655) p-value
Age at transplantation 36.9±11.7 37.6±11.6 0.436
Sex (male proportion;%) 75.7 66.3 0.023
Pre-transplant TB history (%) 19.4 1.2 <0.0001
Relation (LRD: LURD: Deceased) 76: 66: 2 1410: 1105: 140 0.097
Major IS agents (proportion of AZA; %) 10.4 4.0 <0.0001
AR within 1 year 36.8 29.1 0.050
PTDM (%) 36.1 25.5 0.006
HBsAg positive (%) 11.1 4.5 0.001
Anti-HCV positive (%) 4.9 5.4 0.853
Table 1. Clinical manifestations of post-transplant TB patients and non-TB patients.
TB – tuberculosis; LRD – living related donor; LURD – living unrelated donor; IS – immunosuppression; AZA – azathioprine; AR – acute rejec-
tion; PTDM – post-transplant diabetes mellitus.
Variables Positive tuberculin skin test (n=185)* Negative tuberculin skin test (n=373) P-value
Post-transplant TB  4 (2.2%)  3 (0.8%) 0.228
Non-TB  181 (97.8%)  370 (99.2%)
Complementary Table 1. Post-transplant TB occurrence according to the pre-transplant tuberculin skin test.
* Positive tuberculin skin test ≥5 mm. TB – tuberculosis.
Original Paper Ann Transplant, 2013: 18: 163-173
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who had pre-transplant history of TB. However, 
male recipients, AZA-based immunosuppres-
sion, HBV carrier, and a pre-transplant history of 
TB were significantly correlated with the devel-
opment of TB in the 1984–1996 era. The triple 
immunosuppressive regimen with MMF started 
in 1997, and our data showed a significant dec-
rement in the incidence of acute rejection with-
in 1 year post-transplant (from 35.6% to 22.1%, 
P<0.0001). Recipient sex, HBV infection, and 
AZA-based immunosuppression led to limited 
risk during the transplant era before 1997, and 
they were no longer risk factors in the period af-
ter 1997. On the other hand, acute rejection epi-
sodes led to a significant difference in risk accord-
ing to the transplant era. Based on the incidence 
analysis, an acute rejection episode was a risk fac-
tor for post-transplant TB only in the transplant 
era after 1997. Before 1997, 78 (7.9%) of 988 
recipients without acute rejection episodes had 
post-transplant TB, and 42 patients (7.7%) of 
546 recipients with acute rejection episodes had 
post-transplant TB (P=0.921). After 1997, how-
ever, there were significantly different TB inci-
dences from each group (1.3% in the no acute 
rejection episode group vs. 3.9% in the acute re-
jection episode group; P=0.010). As distinct from 
the other risk factors, pre-transplant history of TB 
was the sole and potent risk factor throughout 
the transplant era. Regardless of the transplant 
era, recipients with a pre-transplant history of TB 
had significantly higher risk for post-transplant 
TB (HR=11.618; P<0.0001) (Table 2).
Location of TB
According to the WHO classification, TB was di-
vided into 2 groups: 1) pulmonary TB involving 
miliary TB and solitary lung disease; and 2) ex-
trapulmonary TB involving TB pleurisy and single 
or multiple extrapulmonary lesions. Pulmonary 
TB was the most common form of the disease in 
our series (98/144 [68.1%]). Extrapulmonary TB 
occurred in 46 patients (31.9%), and involved the 
intestines (9/144 [6.3%]), bone (2/144 [1.4%]), 
soft tissue (5/144 [2.8%]), central nervous sys-
tem (3/144 [2.1%]), and other disseminated TB 
(2/144 [1.4%]). The clinical parameters of the 
pulmonary and extrapulmonary types of TB were 
not significantly different. TB pleurisy tended to 
occur in a younger age group than other pulmo-
nary types of TB (P=0.030). TB pleurisy also had 
a greater proportion of males compared with 
other subgroups (P=0.011) (Table 3). Although 
there was no statistically significant difference, 
miliary TB occurred later in the post-transplant 
period (76.9±60.9 months) compared with the 
other subtypes of TB (40–50 months).
Therapeutic results
With the exception of 2 cases of ongoing anti-tu-
berculosis therapy, the overall curative rate was 
76.1% (108/142). Among the 108 cured patients, 
there were 5 reactivation cases (4.7%) that need-
ed retreatment. All 5 reactivation cases had been 
completely treated with proper antituberculosis 
Variables 
1979–1983 (n=85) 1984–1996 (n=1449) 1997–2008 (n=1265)
P-value Hazard ratio
CI (95%)
P-value Hazard ratio
CI (95%) 
P-value Hazard ratio
CI (95%)
lower upper lower upper lower upper
Gender of recipient 
(male) 0.892 1.116 0.229 5.443 0.037 1.624 1.029 2.562 0.776  0.885  0.383  2.047
Age of recipient 
(≥35 yr) 0.173 2.437 0.677 8.781 0.382 0.838  0.565  1.244 0.079  0.467  0.200  1.091
AZA-based IS – – – –  0.028 2.793 1.114  6.998 – – – –
Acute rejection 
within 1 yr following 
transplantation
0.990 0.000 0.000 – 0.108 1.383  0.931  2.056 0.006  3.181  1.401  7.223
PTDM 0.995 1.005 0.243 4.156 0.391 1.199  0.792  1.815 0.081  2.206  0.908  5.361
HBsAg positive 0.360 2.166 0.415 11.317  0.001 2.959  1.593  5.496  0.261  2.316  0.536 10.019
Anti-HCV positive – – – – 0.343 0.669  0.292  1.534 0.639  1.619  0.217 12.093
Pre-tx tuberculosis – – – – <0.0001 9.695  6.212 15.129 0.001 31.240  3.905 249.916
Table 2. Risk factors affecting the development of tuberculosis by Cox regression analysis.
AZA – azathioprine; IS – immunosuppression; PTDM – post-transplant diabetes mellitus; CI – confidence interval; Pre-tx – Pre-transplant.
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regimen at the first diagnosis of post-transplant 
TB. The mean duration from finishing the treat-
ment for the first TB to the second TB diagno-
sis was 20.0±20.3 months. In the 142 cases of TB, 
there were 15 graft losses (10.6%) and 16 fatali-
ties (11.3%) during TB treatment. Among the TB-
related graft losses and mortalities, there were 20 
cases (64.5% [20/31]), including 4 cases of im-
munosuppressive agent modulation failure, 9 cas-
es of sepsis due to primary TB, 3 cases of central 
nervous system TB, and 4 cases of acute deterio-
ration of graft function. Miliary TB and non-pleu-
risy extrapulmonary TB had a lower complete cu-
rative rate than the other types. TB pleurisy was 
the most curable subtype, with a 92.0% curative 
rate (P=0.001). TB-related graft failure or patient 
death occurred in 26.1% and 23.8% of the miliary 
and non-pleurisy extrapulmonary types of TB, re-
spectively, but occurred in 12.0% of the primary 
pulmonary type; no graft or patient loss occurred 
in the TB pleurisy type (P=0.015) (Table 3).
TB history did not affect the cure rate. Of the 28 
recipients who had a history of TB, 20 patients 
were completely cured (cure rate=71.4%), which 
was similar to the patients without a history of 
TB (87/116 [27.0%]) (P=0.375).
Graft and patient survival
During the mean 164±73.2 months of follow-up, 
15 cases of graft loss and 16 cases of patient death 
occurred in the post-transplant TB group. TB 
negatively affected the graft, death-censored graft, 
and patient survival rates. There was a significant 
difference in the cumulative graft survival rate 
between the non-TB and TB groups (Figure 2). 
The non-TB group had 72.49% and 55.16% graft 
survival rates at 10 and 20 years, respectively, but 
the TB group had 58.31% and 29.49% graft sur-
vival rates, respectively (P<0.0001). The TB group 
had a significantly lower patient survival rate 
than the non-TB group (P=0.0003). Based on 
Clinical manifestations
Pulmonary (n=98) Extrapulmonary (n=46)
P-value
Lung (75) Miliary (23) TB pleurisy (25) Others (21)
Characteristics
 Gender (M: F) 60: 15 14: 9 23: 2 12: 9 0.011
 Age at diagnosis 42.5±12.9 45.6±9.9 35.7±10.5 40.4±11.5 0.030
  Interval between transplantation 
and TB diagnosis (months) 54.5±46.5 76.9±60.9 50.4±43.7 42.2±36.3 0.087 
 AR within 1 year  22 (29.3%)  12 (52.2%)  10 (40.0%)  9 (42.9%) 0.205
 Tuberculosis history  11 (14.7%)  3 (13.0%)  8 (32.0%)  6 (28.6%) 0.149
Transplant era (before 1997)  61 (81.3%)  20 (87.0%)  21 (84.0%)  18 (85.7%) 0.960
Therapy
 Anti-tuberculosis regimens
  RFP (+)
  SM (+)
 39 (52.0%)
 15 (20.0%)
 12 (52.2%)
 5 (21.7%)
 11 (44.0%)
 4 (16.0%)
 11 (52.4%)
 4 (19.0%)
0.910
0.977
 Duration of therapy (months) 10.4±5.7 11.0±5.4 11.4±4.8 9.9±6.5 0.790 
Therapeutic results
 Complete cured  59 (78.7%)  14 (60.9%)  23 (92.0%)  14 (66.7%)
0.001
 Incomplete cured  0 (0.0%)  0 (0.0%)  1 (4.0%)  0 (0.0%)
 Graft failure during medication  11 (14.7%)  2 (8.7%)  1 (4.0%)  1 (4.8%)
 Patient death during medication  3 (4.0%)  7 (30.4%)  0 (0.0%)  6 (28.6%)
 On medication  2 (2.7%)  0 (0.0%)  0 (0.0%)  0 (0.0%)
  Tuberculosis-related graft failure or 
patient death 9 (9/75, 12.0%) 6 (6/23, 26.1%)  0 (0.0%) 5 (5/21, 23.8%) 0.015
Table 3. Clinical manifestations and therapeutic results of post-transplant tuberculosis according to the type of post-transplant tuberculosis.
AZA – azathioprine; IS – immunosuppressive agent; RFP – rifampicin; SM – streptomycin.
Original Paper Ann Transplant, 2013: 18: 163-173
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multivariate survival analysis with other variables 
(the gender and age of the recipient, donor type, 
HLA identity, re-transplantation, pre-transplant 
diabetes, hepatitis B virus status, main immuno-
suppressive agent, and episodes of acute rejec-
tion), post-transplant TB was a significant inde-
pendent variable affecting the graft and patient 
survival (graft survival odds ratio [OR] =1.267) 
(P=0.040; patient survival OR=1.505, P=0.021).
There was no significant difference in the 
graft survival rate between each subtype of TB. 
However, in the earlier post-diagnosis period, the 
miliary and non-pleurisy extrapulmonary types 
had lower graft survival rates and then exhibit-
ed a convergent survival rate to the other types 
of TB (Figure 3A). There was no significant dif-
ference between each group with respect to the 
post-diagnosis patient survival rates (Figure 3B). 
However, non-pleurisy extrapulmonary TB had 
the worst patient survival rate, especially com-
pared with the pleurisy type of TB (P=0.038).
discussion
The incidence of post-transplant TB in renal 
transplantation recipients in Western countries 
Figure 2.  Effects of tuberculosis on graft and patient survival rates. 
(A) Graft survival rate: The non-TB group had a 72.49% and 
55.16% graft survival rate at 10 and 20 years, respectively, 
but the TB group had a graft survival rate of 58.31% and 
29.49%, respectively (P<0.0001). (B) The TB group showed 
a worse death-censored graft survival rate than the non-
TB group (P<0.0001). (C) Patient survival rate: The non-
TB group had a 88.06% and 80.09% patient survival rate 
of 10 and 20 years, respectively, and the TB group had a 
patient survival rate of 82.49% and 60.23%, respectively 
(P=0.0003). TB – tuberculosis.
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C Figure 3.  Post-tuberculosis graft survival (A) and patient survival 
rates (B) of each subtype of tuberculosis. TB – tuberculosis.
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ranges from 0.5% to 4% [12,13]. In contrast, 
the incidence of TB in the endemic area is sig-
nificantly greater (13.3% in India, 3.9% in Iran, 
3.84% in Thailand, and 3.5% in Turkey) [2,3,6,7]. 
This study showed a 5.1% overall incidence 
of TB, which is a higher rate than the gener-
al population. In 2007, the incidence of TB in 
the Korean general population was reported as 
71.6 per 100,000 persons by the Korean National 
Tuberculosis Association [11]; compared with the 
general population, the incidence of post-trans-
plant TB in this study increased 70-fold.
According to the first description by Rubin et 
al [14], the peak incidence of TB was between 
3 months and 3 years after renal transplanta-
tion. In a TB endemic area, the overall peak in-
cidence has been reported to occur in the first 
post-transplant year [15]. The current study also 
showed the overall peak incidence of TB within 
1 year following transplantation. Among all TB 
patients, 17.4% (25/144) of patients were di-
agnosed with TB within 1 year following trans-
plantation and 45.1% (65/144) of patients were 
diagnosed with TB within 3 years following trans-
plantation. However, the mean interval between 
transplantation and the diagnosis of TB was rela-
tively long (55.6±47.9 months). In contrast, post-
transplant TB occurred 3 years following trans-
plantation in 54.9% of the recipients. Also, the 
current study showed a consistent interval inci-
dence without a peak per every post-transplant 
year until 8 years after transplantation. Not only 
was the peak incidence within 1 year, but the 
consistent incidence after 1 year was a different 
characteristic of post-transplant TB in the cur-
rent study as performed in a TB endemic area.
A pre-transplant history of TB, HBsAg, anti-HCV 
antibody, diabetes (including PTDM), an acute 
rejection episode, a major immunosuppressive 
agent, and use of ALA are considered to be risk 
factors for post-transplant TB [16–20]. The cur-
rent study showed that acute rejection within 1 
year following transplantation and a pre-trans-
plant history of TB were statistical risk factors 
for TB infection in recent years. Among the 
risk factors, a pre-transplant history of TB was 
the strongest risk factor. Based on risk analysis, 
AZA-based immunosuppression was one of the 
risk factors for post-transplant TB in the 1984–
1996 era. In our experience, the AZA-based im-
munosuppression group had a relatively small 
population (n=120, 4.29%) and was comprised 
of extremely early transplantation cases (before 
1986). Also, in the period when AZA was used 
as a major immunosuppressive agent, the prev-
alence of TB in the general population of Korea 
was 3 times higher than the subsequent period 
[11]. Therefore, AZA-based immunosuppression 
is not an independent risk factor for post-trans-
plant TB. In risk analysis only for the era between 
1984 and 1986, which was the period when we 
used AZA or CsA as a major immunosuppressive 
agent, AZA was no longer a risk factor for post-
transplant TB (HR, 1.272; 95% CI, 0.389–4.156, 
P=0.690; data not shown).
We identified a change in risk factors as a func-
tion of the transplant era. This change might be 
due to controlling some factors affecting TB. For 
example, an anti-hepatitis B viral agent has been 
used from 1999 in Korea. However, excessive im-
munosuppression for treatment of acute rejection 
and pre-transplant TB history cannot be avoided. 
A previous history of TB and acute rejection re-
mains a risk factor for post-transplant occurrence. 
In 2,799 renal transplant recipients, there were 
61 patients who had pre-transplant TB. Among 
them, 28 recipients (45.9%) had post-transplant 
TB. About one-half of the patients who had a pre-
transplant history of TB acquired post-transplant 
TB. It is possible that latent TB was reactivated 
after immunosuppression. In the current study, 
of the 28 patients with a pre-transplant history 
of TB, 12 patients (42.8%) had acute rejections 
and treatment within 1 year post-transplant. We 
do not routinely use ALA as an induction ther-
apy for living donor kidney transplantation, ex-
cept for a small number of deceased donor kid-
ney transplantations. An acute rejection episode 
was a risk factor for post-transplant TB in the cur-
rent study. This was thought to result from the 
rescue therapy for acute rejection using steroid 
pulse therapy or ALA. As we know, severe immu-
nosuppression during rescue therapy is related 
to co-infection.
The Centers for Disease Control and Prevention 
(CDC) guidelines recommend at least 9 months 
of prophylaxis with INH for high-risk transplant 
recipients [21]. Indications for prophylaxis also 
include a history of TB contact before transplan-
tation, patients who have been newly infected 
with M. tuberculosis (ie, those with a recent PPD 
conversion), and recipients of transplants from 
donors with a history of untreated TB [22]. In 
the current study, 19.4% (28/144) of the recip-
ients had a pre-transplant history of TB. We did 
not administer INH prophylaxis. Thus, this was a 
limitation of the current study. However, of the 28 
patients with a previous history of TB infection, 
Original Paper Ann Transplant, 2013: 18: 163-173
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only two patients had post-transplant TB 1 year 
after the post-transplant period. The median du-
ration between transplantation and the diagnosis 
of TB was 38.5 months (range, 0–160 months). 
The mean duration between transplantation and 
the diagnosis of TB was not different from the 
group without a history of TB; there was also no 
significant difference in the cure rate between 
the patients with no TB history. TB prophylax-
is for transplant recipients is controversial, es-
pecially in endemic areas [23–25]. Prophylaxis 
is effective among renal transplant recipients 
who are living in a country with a low endemici-
ty [12]; however, no such effect was reported in 
a study from India involving 184 kidney trans-
plant recipients [26]. Riska et al. suggested that 
patients for whom TB was completely treated in 
the past do not need new treatment courses or 
prolonged prophylaxis [27].
In the general population, a frequent TB form 
was pulmonary localization in Korea. The pro-
portion of extrapulmonary TB in the endemic 
areas is lower; specifically, 8.3% in Poland [28] 
and 12.2% in Korea [11]. In other areas, however, 
the proportion of extrapulmonary TB in endemic 
areas is higher; for example, 48% in Brazil [29], 
82.5% in the United States [30], and 38% in The 
Netherlands [31]. However, in transplant recipi-
ents it is well-known that the extrapulmonary or 
disseminated organ type of TB is more frequent 
than in the general population [24,32,33]. We 
showed a 31.2% extrapulmonary-type involve-
ment among the TB patients, which is a higher 
proportion of extrapulmonary type of TB than 
12.2% of TB patients in the general population 
in Korea. A predominance of extrapulmonary or 
disseminated-type TB is correlated with a poor 
prognosis in post-transplant recipients.
Our data clearly shows a negative effect of post-
transplant TB on graft and patient survival rates. 
After solid organ transplantation, TB-related graft 
failure and mortality rates have been reported 
to be 10–25% from many countries in endem-
ic areas [34–36]. In the current study, the TB-
related graft failure and mortality rate was 13.9% 
(20/144), which is similar to other reports. In 
addition, this study also showed clear evidence 
of the effect of post-transplant TB on the graft 
and patient survival rate with a long-term follow-
up period. The current study did not show a sig-
nificantly different graft survival rate as a func-
tion of the TB subtype in Kaplan-Meier survival 
rate analysis. However, in earlier periods involv-
ing the post-diagnosis of TB, miliary TB and 
non-pleurisy extrapulmonary TB had worse graft 
survival rates than the other subgroups. Reports 
from endemic areas have revealed similar re-
sults [7,35]. Although the basis of this phenom-
enon is not fully understood, it could be related 
to the unusual clinical presentation of extrapul-
monary TB, which can delay diagnosis and treat-
ment [37]. The current study showed a higher 
TB-related graft failure and mortality rate of mil-
iary and non-pleurisy extrapulmonary TB types 
than the other subtypes. However, with time, the 
graft survival rates of each subtype will converge. 
This can be attributed to the negative effect of 
miliary and other extrapulmonary TB on early 
graft survival, but in the cases in which the grafts 
were completely cured, the natural course of the 
other TB groups could be followed.
This current study is conducted by retrospective 
analysis. Inclusion of cases in which TB diagno-
sis was defined without microbiological method 
could be one of the limitations of the present 
study. In an endemic area, however, TB can be 
diagnosed clinically in condition of favorable re-
sponse to anti-tuberculosis therapy in patients 
with radiologic abnormality indicating TB or fe-
ver of unknown origin when extensive investiga-
tion yielded no clues [3].
Pre-transplant TB screening is important. Our 
center has done tuberculin skin testing for pre-
transplant TB screening since 2001 and interfer-
on-gamma release assay since 2010. A previous 
report about pre-transplant TB risk factor analy-
sis in kidney recipients revealed that positive tu-
berculin skin test and previously healed TB le-
sions visible on pre-transplant chest X-ray were 
significant risk factors and showed a 31.3% pos-
itivity rate in pre-transplant tuberculin skin test-
ing [20]. False positivity in skin tests is common 
in endemic areas because of vaccination. In the 
current study, only 558 recipients were evaluat-
ed with tuberculin skin tests for pre-transplant 
evaluation. Among them, 185 (33.2%) recipi-
ents showed a positive (≥5mm) result. However, 
there was no different in TB occurrence after 
transplantation between the positive and nega-
tive tuberculin skin test groups (data not shown).
conclusions
TB is an important infectious disease for immu-
nocompromised patients in endemic areas. In the 
current study, the most important risk factor for 
post-transplant TB was a pre-transplant history 
of TB. The cure rate of the group of transplant 
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recipients with a pre-transplant history of TB was 
not different from that of the group without a 
history of TB. Thus, we suggest that recipients 
with a pre-transplant TB history should be close-
ly monitored for early detection and treatment.
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